Form 4: Werewolf Therapeutics Director Sells Shares

Luke Evnin, a director at Werewolf Therapeutics, Inc., reported the sale of 134,553 shares of common stock across three transactions in mid-November 2025, executed under a pre-arranged 10b5-1 plan.

Summary

• Luke Evnin, a director of Werewolf Therapeutics, Inc. (HOWL), reported the indirect sale of common stock.
• Transactions occurred on November 13, 2025, November 14, 2025, and November 17, 2025.
• A total of 134,553 shares were sold across these three dates.
• The sales were executed pursuant to a Rule 10b5-1 plan established on September 24, 2025.
• The shares were sold indirectly through various MPM entities, including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P.
• Following these transactions, the indirect beneficial ownership stands at 3,515,880 shares.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a director's reduction in indirect beneficial ownership. While the sales were pre-planned under a Rule 10b5-1 plan, which mitigates the immediate negative signal, the act of selling shares, especially at prices below $1.00, can still be interpreted by the market as a lack of strong conviction in significant near-term price appreciation.

Positives

• The sales were conducted under a pre-established Rule 10b5-1 plan, indicating they were not a reaction to recent negative news or an attempt to profit from undisclosed information.

Negatives

• A director, Luke Evnin, reduced his indirect beneficial ownership in the company by 134,553 shares.
• The sales occurred at weighted average prices ranging from $0.93 to $0.98 per share, which are relatively low prices.

Future Outlook

NA

Management Comments

• The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Industry Context

This Form 4 filing details an insider transaction for a biotechnology company. While the sales are pre-planned, they occur in a sector often sensitive to insider sentiment, particularly regarding early-stage or development-focused firms like Werewolf Therapeutics. The relatively low share prices at which the sales occurred could reflect broader market sentiment or specific company performance within the biotech industry.

Related Party Transactions

• The sales were conducted by entities (MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P.) where Luke Evnin has a managerial or membership role, making these indirect transactions by a related party.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially leading to downward pressure on the stock price.
• Management/Employees: Could potentially impact morale if perceived as a lack of confidence from a director, though the 10b5-1 plan context might lessen this.

Key Dates

Recommendation

While insider selling is generally a negative signal, the fact that these sales were executed under a pre-established 10b5-1 plan mitigates the immediate bearish interpretation. It suggests a planned liquidity event rather than a reaction to new, undisclosed negative information. However, the sales occurring at prices below $1.00 could indicate limited near-term upside perceived by the insider. Without additional information on the company's fundamentals or other market catalysts, a 'hold' recommendation is appropriate, advising investors to monitor future developments and broader market trends for Werewolf Therapeutics.

Keywords

Werewolf Therapeutics, HOWL, Luke Evnin, Director, Insider Selling, Form 4, SEC Filing, Stock Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals